Form 4: Director Eduardo Alfonso Acquires Bausch + Lomb Shares

Director Eduardo Alfonso acquired 1,375 restricted share units of Bausch + Lomb Corporation at a price of $15.90 per share.

Summary

• Director Eduardo Alfonso acquired 1,375 restricted share units (RSUs) of Bausch + Lomb Corporation (BLCO).
• The transaction occurred on April 30, 2026.
• The acquisition price was $15.90 per share.
• Following this transaction, the director's total beneficial ownership is 15,230 common shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event, as it represents routine director compensation and alignment rather than a significant strategic shift.

Positives

• Director alignment with shareholder interests through the acquisition of equity.
• The transaction reflects confidence in the company's long-term value.

Negatives

• None identified in this filing.

Risks

• Standard market risks associated with equity ownership in the pharmaceutical and eye health sector.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that director equity acquisitions are common in the healthcare sector and are generally viewed as a positive signal of internal confidence in corporate strategy and valuation.

Comparison to Industry Standards

• The acquisition of restricted share units is a standard component of director compensation packages in large-cap pharmaceutical companies.
• The transaction size is consistent with typical director-level equity holdings for companies of Bausch + Lomb's market capitalization.

Stakeholder Impact

• Provides transparency to shareholders regarding director equity positions.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Bausch + Lomb, BLCO, Insider Trading, Form 4, Director Acquisition, Equity Compensation